ARVO EDUCATION COURSE

Saturday, May 3, 2025
8am – 5pm, MST
Salt Palace Convention Center
Salt Lake City, Utah

The New Era of Uveitis: Embracing Modern Technology

Course organizers

Chairperson: Vishali Gupta, MD

Course Coordinators: Rupesh Vijay Agrawal, MD, FRCS, MMed, Esen K. Akpek, MD, David S. Chu, MD, Phoebe Lin, MD, PhD, Careen Y. Lowder, MD, PhD, Quan Dong Nguyen, MD MSc, FARVO and Carlos E. Pavesio, FRCOphth, MD

Clinical trials in uveitis: What everyone needs to know

Moderators: Lyndell L Lim, MBBS, DMedSci, FARVO and Jennifer Cao, MD, MD, MPH

This session will explore clinical trials for uveitis classification, standardizing imaging nomenclature and incorporating AI tools in uveitis clinical trials. The session will close with a discussion on defining endpoints.

Presentations		
3:30 PM	**Standardizing Uveitis Research to Enhance Future Clinical Trial Comparability and Systematic Reviews: The Standardization of Uveitis Nomenclature (SUN) Experience** Standardization of outcome measures, grading systems, and definitions of outcome measures improves the ability to compare results from different clinical research studies and facilitates systematic reviews. The Standardization of Uveitis Nomenclature (SUN) Working Group was an international group of investigators dedicated to improving the quality of research in the field of uveitis. The First SUN Workshop used formal consensus techniques to standardize several outcomes for uveitis research, inflammation grading schema, and reporting thresholds. The results of this workshop have been widely adopted and used in clinical research. The SUN "Developing Classification Criteria for the Uveitides" Project used a multistep process, including informatics, formal consensus techniques, and machine learning to develop classification criteria for 25 of the more common uveitides, resulting in criteria sets with a high degree of accuracy. These criteria facilitate accurate diagnosis of the specific uveitic entity for enrollment in clinical trials and cohort studies.	Douglas A. Jabs, MD, MBA

3:45 PM	**Standardizing nomenclature for uveitis clinical trials** There is considerable variation in the descriptors for posterior uveitis lesions and imaging This presentation will cover the key features of MFCFU and PIC using examples with multimodal imaging to describe lesions and activity of lesions.	Sapna Gangaputra, MD, MPH
4:00 PM	**Defining Endpoints in Uveitis Trials** Edmund Tsui, MD, MS will discuss key clinical and imaging endpoints used to evaluate treatment efficacy in uveitis clinical trials. This talk will cover traditional measures, such as anterior chamber cell and flare, vitreous haze, retinal and choroidal lesions, and vascular leakage, as well as novel imaging biomarkers including OCT-based metrics. This talk will emphasize the importance of selecting standardized, validated endpoints to ensure consistency across trials and facilitate comparison of therapeutic outcomes. Additionally, Dr. Tsui will highlight challenges in endpoint selection given the heterogeneity of uveitis subtypes and evolving treatment modalities.	Edmund Tsui, MD, MS
4:15 PM	**Questions and answers**	All
4:50 PM	**Concluding remarks**	Vishali Gupta, MD

*Presenters and presentations are subject to change without notice.